

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2016/044436 A2

(43) International Publication Date

24 March 2016 (24.03.2016)

WIPO | PCT

(51) International Patent Classification:

C07K 16/40 (2006.01) G01N 33/569 (2006.01)

(21) International Application Number:

PCT/US2015/050449

(22) International Filing Date:

16 September 2015 (16.09.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/051,130 16 September 2014 (16.09.2014) US
62/089,054 8 December 2014 (08.12.2014) US

(71) Applicant: OVASCIENCE, INC. [US/US]; 215 First Street, Suite 240, Cambridge, MA 02142 (US).

(72) Inventors: WEAVER, David, T.; 6 Audubon Dr., Newton, MA 02467 (US). ZHANG, Bo; 14 Village Row, Lynnfield, MA 01940 (US).

(74) Agents: TWOMEY, Michael, J. et al.; Wilmer Cutler Pickering Hale And Dorr LLP, 60 State Street, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: ANTI-VASA ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF

Human VASA Amino Acid Sequence

(Accession: NP_077726; SEQ ID NO: 1)

1 modedweaei nphmssyppi fekdrysgen qdnfnrtpas ssemddgprsr rdhfmksgfa
51 sgrnfgnnda gecnkrants tmqffgvqks fgnrqrfsnsr fedgdsscfw ressnndcedn
121 ptrnrqfkskr ggyrdrqnse ascpypyrrgrg qsfqrqrgqf glgspnnld pdecmqrtcq
181 lfgssrrpvls gtqngdtsqs rsgsgseerg ykglnneevit gsgknswkse aegcessdtq
241 gpkvtyippp poededsifa hygtginfdk ydtivilvevsg hdappailtf eeanlcqtlm
301 nniakagytk ltpvqkysip iilagrdlma caqtsgkta aflpilahm mhgditasrf
361 kelqepecil vaptrelvng iylearkfsf qtcvravvly ggtqlghsir qivqgcnlrc
421 atpgrlmdii qkekiglkqi kylvldeadr mldmgfgpem kkliscpcgp skeqrqtlmf
481 satfpeeiqr laaeflknsy lfvavqgqvgg acrdvqqtvl qvqgqfskrek lveilrnigd
541 ertmwfvetk kkadfiatfl cgekisttsi hgdreqrere qalgdfrfck cpvlvatsva
601 argldienvg hyinfldpst idevvhrigr tgrcqntgra isffcllesdn hlaoplykv
661 tdaqqgvaw leelafstyli pgfsgstrgn vfasvdtirk gkstlntagfs ssqapnpvdd
721 eswd

FIG. 1

(57) Abstract: Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti- VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.

ANTI-VASA ANTIBODIES, AND
METHODS OF PRODUCTION AND USE THEREOF

[0001] This application claims the benefit of priority of U.S. Provisional Application No. 62/051,130, filed September 16, 2014, and U.S. Provisional Application No. 62/089,054, filed December 8, 2014, the entire contents of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present disclosure relates generally to antibodies, their production and use. Specifically, the present disclosure pertains to antibodies which specifically bind to the human VASA protein, methods of producing such antibodies, and diagnostic, therapeutic and clinical methods of using such antibodies.

BACKGROUND

[0003] The VASA protein was identified in *Drosophila* as a component of the germplasm that encodes a DEAD-family ATP-dependent RNA helicase (Liang *et al.* (1994), *Development*, 120:1201-11; Lasko *et al.* (1988), *Nature* 335:611-17). The molecular function of VASA is directed to binding target mRNAs involved in germ cell establishment, oogenesis, and translation onset (Gavis *et al.* (1996), *Development* 110:521-28). VASA is required for pole cell formation and is exclusively restricted to the germ cell lineage throughout development.

[0004] *Vasa* homolog genes have been isolated in various animal species, and VASA can be used as a molecular marker for the germ cell lineage in most animal species (Noce *et al.* (2001), *Cell Structure and Function* 26:131-36). Castrillon *et al.* (2000), *Proc. Natl. Acad. Sci. (USA)* 97(17):958590-9590, for example, demonstrated that the human *Vasa* gene is expressed in ovary and testis but is undetectable in somatic tissues.

[0005] The existence of mammalian female germline stem cells, also known as oogonial stem cells or ovarian stem cells (OSCs) or egg precursor cells, in the somatic tissue of mammalian ovaries was first described in Johnson *et al.* (2004), *Nature* 428:145-50, and has now been confirmed by other research groups (e.g., Zou *et al.* (2009), *Nature Cell Biology*, published online DOI: 10.1038/ncb1869; Telfer & Albertini (2012), *Nature Medicine*

18(3):353-4). The potential use of OSCs to produce oocytes for use in artificial reproduction technologies (ART), including *in vitro* fertilization (IVF), or as sources of highly functional mitochondria for mitochondrial transfer to oocytes, as well as the use of OSCs to treat various symptoms of menopause, have been described in the scientific and patent literature (e.g., Tilly & Telfer (2009), *Mol. Hum. Repro.* 15(7):393-8; Zou *et al.* (2009), *supra*; Telfer & Albertini (2012), *supra*; White *et al.* (2012), *Nature Medicine* 18(3):413-21; WO 2005/121321; U.S. Pat. No. 7,955,846; U.S. Pat. No. 8,652,840; WO2012/142500; U.S. Pat. No. 8,642,329 and U.S. Pat. No. 8,647,869).

[0006] When OSCs were first characterized by Johnson *et al.* (2004), *supra*, it was demonstrated that the cells expressed the VASA protein, and antibodies against the VASA protein have been used to isolate OSCs from ovarian tissue homogenates (e.g., Zou *et al.* (2009), *supra*; White *et al.* (2012), *supra*). Moreover, White *et al.* (2012), *supra*, demonstrated that antibodies to an N-terminal domain of VASA could not be used to isolate viable VASA-expressing OSCs whereas antibodies to a C-terminal domain could effectively isolate the cells, suggesting that the C-terminal domain, but not the N-terminal domain, was extracellular and thus accessible to the antibodies.

[0007] The production of anti-VASA polyclonal antibodies was first described in Castrillon *et al.* (2000), *supra*, and WO01/36445. Polyclonal antibodies directed to the C-terminal portion of human VASA protein are commercially available from Abcam plc (Cambridge, UK; Product Code AB13840), and R&D Systems, Inc. (Minneapolis, MN; Catalog No. AF2030), and a monoclonal antibody directed against the N-terminal portion of human VASA is also commercially available from R&D Systems, Inc. (Minneapolis, MN; Catalog No. AF2030),

[0008] There remains, however, a need for high affinity antibodies directed to the C-terminal extracellular domain of VASA for identifying (e.g., by immunohistochemistry or labeled antibodies) and isolating (e.g., by magnetic or fluorescence activated cell sorting) cells, including but not limited to OSCs, expressing VASA.

SUMMARY

[0009] Anti-VASA antibodies (mAbs), particularly humanized mAbs that specifically bind to VASA with high affinity, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of

these anti-VASA mAbs are provided. The disclosure also provides nucleic acid molecules encoding the anti-VASA mAbs, expression vectors, host cells, methods for making the anti-VASA mAbs, and methods for expressing the anti-VASA mAbs. Finally, methods of using the anti-VASA mAbs to isolate and/or purify cells expressing VASA are disclosed.

[0010] These and other aspects and embodiments of the disclosure are illustrated and described below. Other systems, processes, and features will become apparent to one with skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional systems, processes, and features be included within this description, be within the scope of the present invention, and be protected by the accompanying claims.

BRIEF DESCRIPTION OF THE FIGURES

[0011] FIGURE 1 provides the amino acid sequence of the human VASA protein isoform 1 from GenBank Accession from NP_077726 (SEQ ID NO: 1).

[0012] FIGURE 2 provides the amino acid sequence of the mouse VASA homolog protein isoform 1 from GenBank Accession from NP_001139357 (SEQ ID NO: 2).

[0013] FIGURE 3 provides an amino acid alignment between the C-terminal portion of the human VASA protein (residues 690-724 of SEQ ID NO: 1) and the mouse VASA homolog (residues 691-728 of SEQ ID NO: 2).

[0014] FIGURE 4A shows the region of the C-terminal domains of the VASA/DDX4 polypeptide that is reactive with an antibody of the invention and the control antibody (AB13840, Abcam plc, Cambridge, UK) and FIGURE 4B shows binding of the control antibody to the VASA protein and the V1 and V2 polypeptides.

[0015] FIGURE 5A shows dose response binding curves of the affinity for VASA of 1E9 and 1A12; and FIGURE 5B shows the results of ELISA assays with the VASA, V1 and V2 peptides that suggest that 1E9 binds the same epitope as the commercially available rabbit polyclonal antibody (AB13840, Abcam plc, Cambridge, UK). NC = negative control; VASA = SEQ ID NO: 1 residues 700-724; VASA-1 = V1 or SEQ ID NO: 1 residues 712-721; VASA-2 = V2 or SEQ ID NO: 1 residues 700-709.

[0016] FIGURE 6A shows dose response binding curves of the affinity for VASA of the IgG and scFv-Fc forms of 1E9; and FIGURE 6B shows the results of ELISA assays of the binding of the IgG and scFv-Fc forms of 1E9 with the VASA, V1 and V2 peptides. NC =

negative control; VASA = SEQ ID NO: 1 residues 700-724; VASA-1 = V1 or SEQ ID NO: 1 residues 712-721; VASA-2 = V2 or SEQ ID NO: 1 residues 700-709.

[0017] FIGURE 7A shows the results of binding experiments with three anti-VASA hybridoma antibodies (2M1/1K3, 2M1/1K23 and 2M1/1L5) and two negative controls (2M1/1F5 and 2M1/1H5) which are not VASA-specific; FIGURE 7B shows dose response curves of four VASA-specific hybridoma antibodies (2M1/1K3, 2M1/1K23 and 2M1/1L5) compared to 1E9-lambda; and FIGURE 7C shows dose response curves of the VASA-specific hybridoma antibody 2M1/2K4 compared to 1E9-lambda.

[0018] FIGURE 8 shows the result of subtyping analysis for anti-VASA antibodies from eight hybridomas (2M1/1L20, 2M1/1J20, 1M1/1C9, 2M1/1N3, 2M1/1K23, 1M1/1L5 and 2M1/2K4).

[0019] FIGURES 9A-9B show alignments of some of the VL sequences of the anti-VASA invention. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.

[0020] FIGURES 10A-10B show alignments of some of the VH sequences of the anti-VASA invention. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.

[0021] FIGURE 11 shows alignments of the unique CDR sequences of the VL regions of Figure 9.

[0022] FIGURE 12 shows alignments of the unique CDR sequences of the VH regions of Figure 10.

DETAILED DESCRIPTION

[0023] The present disclosure relates to isolated antibodies (Abs), particularly Abs that bind specifically to VASA with high affinity. In certain embodiments, the anti-VASA Abs are derived from particular heavy and light chain sequences and/or comprise particular structural features, such as CDR regions comprising particular amino acid sequences. This disclosure provides isolated anti-VASA Abs, methods of making such anti-VASA Abs, immunoconjugates and bispecific molecules comprising such anti-VASA Abs, and methods of expressing such anti-VASA Abs. This disclosure also relates to methods of using the anti-VASA Abs to isolate and/or purify cells expressing VASA, including mammalian female

germline stem cells or oogonial stem cells (OSCs) or egg precursor cells and their progenitor cells.

[0024] In order that the present disclosure may be more readily understood, certain terms are defined. Additional definitions are set forth throughout the detailed description.

Definitions

[0025] The term “antibody” or abbreviation “Ab,” as used herein, includes whole antibodies and any antigen binding fragment (*i.e.*, “antigen-binding portion”) or single chains thereof, with or without native glycosylation. A complete “antibody” refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds or an antigen binding portion thereof. Each heavy chain includes a heavy chain variable region (V_H) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, C_{H1}, C_{H2}, and C_{H3}. Each light chain includes a light chain variable region (V_L) and a light chain constant region with one domain, C_L. The V_H and V_L regions can be further subdivided into complementarity determining regions (CDR) and framework regions (FR). The V_H and V_L regions each include three CDRs, designated CDR1, CDR2 and CDR3, that interact with an antigen (*e.g.*, VASA).

[0026] The term “antigen-binding portion” of an antibody, as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (*e.g.*, VASA). Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include a Fab fragment, F(ab')₂ fragment, Fab' fragment, Fd fragment, Fv fragment, scFv fragment, dAb fragment, and an isolated CDR.

[0027] The term “monoclonal antibody” or “monoclonal antibody preparation,” as used herein, refers to a preparation of antibody molecules consisting essentially of antibodies having a single heavy chain amino acid sequence and a single light chain amino acid sequence (but which may have heterogeneous glycosylation).

[0028] The term “humanized antibody,” as used herein, includes antibodies having constant region and variable region framework regions (FRs) but not CDRs derived from human germline immunoglobulin sequences.

[0029] The term “recombinant antibody,” as used herein, includes all antibodies prepared, expressed, created, or isolated by recombinant means. In certain embodiments, recombinant antibodies are isolated from a host cell transformed to express the antibody (*e.g.*,

from a transfectoma). In other embodiments, recombinant antibodies are isolated from a recombinant, combinatorial antibody library, such as a phage display library. Recombinant antibodies may also be prepared, expressed, created, or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences.

[0030] The term “isotype,” as used herein, refers to the heavy chain class (e.g., IgA, IgD, IgE, IgG, and IgM for human antibodies) or light chain class (e.g., kappa or lambda in humans) encoded by the constant region genes. The term “subtype” refers to subclasses within the subtype (e.g., IgA₁, IgA₂, IgG₁, IgG₂, IgG₃, IgG₄ in humans).

[0031] The phrase “an antibody specific for” a specified antigen is used interchangeably herein with the phrase “an antibody which specifically binds to” a specified antigen. As used herein, the term “K_a” refers to the association rate and the term “K_d” to the dissociation rate of a particular antibody-antigen complex. The term “K_D” refers to the dissociation constant, which is obtained from the ratio of K_d to K_a and expressed as a molar concentration (M). According to some embodiments, an antibody that “specifically binds to human VASA” is intended to refer to an antibody that binds to human VASA with a K_D of 5×10⁻⁸ M or less, more preferably 1×10⁻⁸ M or less.

[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Anti-VASA Antibodies

[0033] The invention provides a variety of new antibodies with high affinity against the human VASA protein, particularly the C-terminal region. The antibodies may comprise the complete VH and VL regions disclosed herein, or may comprise only the CDR sequences disclosed herein. In addition, based upon CDR sequences disclosed herein, sequence motifs for CDR sequences are provided, and the antibodies may comprise CDR sequences defined by the motifs.

[0034] The CDR sequences of the invention (including both the CDRs disclosed in Figures 11 and 12 and the CDRs defined by the sequence motifs disclosed herein) can be combined with other immunoglobulin sequences according to methods well known in the art to produce immunoglobulin molecules with antigen-binding specificity determined by the CDRs of the invention.

[0035] In some embodiments, the CDRs of the invention are combined with framework region (FR) and constant domain (CH or CL) sequences from other antibodies. For example, although some of the CDRs disclosed herein are derived from murine hybridomas and have murine FR and constant domain sequences, they can be recombined with human or other mammalian FR and constant domain sequences to produce humanized or other recombinant antibodies. The production of such recombinant antibodies is well known to those of skill in the art and requires only routine experimentation.

[0036] The type of constant regions included in such recombinant antibodies can be chosen according to their intended use. For example, if the antibodies are intended for therapeutic use to target VASA-expressing cells for destruction, heavy chain constant domains (*i.e.*, Fc regions) of IgG subtypes can be used. If the antibodies are intended only as reagents for labeling cells (*e.g.*, for fluorescence-activated cell sorting (FACS)), a complete antibody, antigen binding fragment (Fab), single-chain variable fragment (Fsc), single domain antibody (sdAb) or even non-antibody immunoglobulin molecule (*e.g.*, an MHC receptor extracellular domain) can be used with the CDRs of the invention.

[0037] The CDRs of the invention can be selected independently such that the CDR1, CDR2 and CDR3 sequences of a given variable light (VL) chain or variable heavy (VH) chain can be chosen from different original VL and VH chains, from different VL and VH CDR motifs, or from a combination of the disclosed CDRs and motifs. However, sequences for light chain CDRs should be selected from the disclosed VL CDRs or VL CDR motifs, and sequences for heavy chain CDRs should be selected from the disclosed VH CDRs or VH CDR motifs. Similarly, the sequences for CDR1 regions should be selected from the disclosed CDR1 or CDR1 motif sequences, the sequences for CDR2 regions should be selected from the disclosed CDR2 or CDR2 motif sequences, and the sequences for CDR3 regions should be selected from the disclosed CDR3 or CDR3 motif sequences, for VL or VH chains as appropriate.

Methods of Using Anti-VASA Antibodies to Detect or Isolate Cells

[0038] The anti-VASA antibodies of the invention can be used in standard methods of immunoaffinity purification, immunohistochemistry and immunotherapy, but with specific application to cells and tissue expressing the VASA protein.

[0039] For example, the anti-VASA antibodies of the invention can be used to isolate cells expressing VASA from a mixed population of cells including only a fraction of cells that express VASA. For example, female germline stem cells or oogonial stem cells or their precursors have been discovered to be present in ovarian tissue at very low proportions. Ovarian tissue (*e.g.*, ovarian surface epithelial and/or cortex) can be excised, dissociated into individual cells, and subjected to techniques such as FACs using fluorescently-labeled anti-VASA antibodies or immunoaffinity purification using immobilized anti-VASA antibodies. The isolated VASA-expressing cells have various utilities in assisted reproductive technologies, as described above.

[0040] Alternatively, immunohistochemistry may be performed using the anti-VASA antibodies of the invention to identify cells or tissues expressing VASA and/or to quantify VASA expression in such cells.

[0041] In addition, the anti-VASA antibodies of the invention can be used therapeutically to target VASA-expressing cells for destruction either by antibody-dependent cell-mediated cytotoxicity (ADCC) or immunotoxins comprising anti-VASA antibodies of the invention conjugated to radio- or chemo-toxic moieties. Antibody-drug conjugates of the anti-VASA antibodies of the invention could also be used to deliver therapeutic drugs to VASA-expressing cells.

Nucleic Acid Molecules Encoding Anti-VASA Antibodies

[0042] The invention also provides nucleic acid molecules encoding the anti-VASA antibodies of the invention. Such nucleic acids can be designed using standard tables for the universal genetic code to choose codons which will encode the desired amino acid sequence, or specialized codon tables can be used that reflect codon biases characteristic of different organisms. Thus, for example, to optimize expression of the anti-VASA antibodies of the invention in CHO cells, a nucleic acid encoding the desired antibody can be designed using a codon table optimized for CHO cells.

[0043] The nucleic acids encoding the anti-VASA antibodies of the invention can be included in a wide variety of vectors known in the art, including cloning vectors (*e.g.*,

bacterial or mammalian cloning vectors), transformation vectors (e.g., homologous recombination, viral integration or autonomously replicating vectors) and expression vectors (e.g., high copy number, inducible or constitutive mammalian expression vectors).

Cells Expressing Anti-VASA Antibodies

[0044] Also provided are host cells expressing heterologous sequences encoding the anti-VASA antibodies of the invention. Such host cells can be useful for commercial production of the anti-VASA antibodies of the invention, and can be produced by transforming appropriate host cells with expression vectors described above.

[0045] In some embodiments the invention provides mammalian cells, including CHO cells, expressing the anti-VASA antibodies of the invention. However, those of skill in the art can express the antibodies in a variety of host cells, including bacterial, yeast, insect and mammalian systems. See, e.g., Verma *et al.* (1998), *J. Immunol. Methods* 216(1-2):165-81, incorporated by reference in its entirety herein.

EXAMPLES

Immunogenic Peptides

[0046] The following peptides were used as immunogens to generate antibodies against the C-terminal domain of human VASA and to screen for antibodies with high affinity binding to VASA:

 VASA-1 (V1) immunogen: SQAPNPVDDE (SEQ ID NO: 1 residues 712-721)

 VASA-2 (V2) immunogen: GKSTLNTAGF (SEQ ID NO: 1 residues 700-709)

[0047] As shown in Figure 3, these immunogens comprise amino acid sequences from the C-terminal domain of VASA that are highly conserved between the human VASA protein and the mouse VASA homolog.

Hybridoma Generation

[0048] Hybridomas were formed in separate experiments with the VASA peptide immunogens V1 and V2 (above). Peptides were conjugated to carrier proteins by standard methods. Conjugated peptides were used to immunize mice, and to increase the immune response through boosting with the conjugated peptide. Following a period of increased antibody titer in the sera, animals were sacrificed and spleens removed. Splenic B cells were fused to mouse fusion partner cell lines (SP2-0) for isolation and cloning. Hybridomas were

formed by outgrowth at limiting dilution, and clones were developed by cloning titration experiments. The presence of VASA-reactive antibodies was examined by ELISA assays. Hybridomas were derived by outgrowth and stabilization of cells plated at limiting dilution cell cloning.

[0049] The binding of the VASA-reactive antibodies in the region of the C-terminal domains of the VASA/DDX4 polypeptide was compared with the binding control antibodies (AB13840, Abcam plc, Cambridge, UK) to delineate the similarity of the binding epitopes. Exemplary results are shown in Figure 4.

Analysis of hybridomas

[0050] Hybridomas were injected intraperitoneally into mice and, after allowing for a period of growth, ascites fluid was collected and purified, all using standard procedures, and then analyzed by ELISA.

[0051] Binding of the ascites-derived antibodies to the VASA, VASA-1 and VASA-2 polypeptides was used to select antibodies for further analysis. For example, as shown in Figure 7, the binding of four anti-VASA hybridoma antibodies (2M1/1K3, 2M1/1K23, 2M1/1L5 and 2M1/2K4) were compared to two negative controls (2M1/1F5 and 2M1/1H5) which are not VASA-specific and/or to the 1E9-lambda antibody (described below).

Recombinant Library Panning

[0052] As an alternative to hybridoma technology, the generation of antibodies against amino acid residues 700-724 of human VASA/DDX4 was conducted using phage display technology. The phage display library was formed from a pool of normal B cells from ~40 blood donors. Phage were used to display the scFv chain of an antibody

[0053] The results of panning the human naïve scFv library against the VASA/DDX4 700-724 peptide were as shown in Table 1 below:

TABLE 1

Peptide	Round	Titer of output phage (cfu/ml)	Titer of rescued phage (cfu/ml)	ELISA results
VASA	1 st	10 ⁷	10 ¹³	/
	2 nd	10 ⁷	10 ¹³	/
	3 rd	10 ⁷	10 ¹²	No positive clones
	4 th	10 ⁷	10 ¹³	Two positive clones
	5 th	10 ⁷	10 ¹³	Several positive clones
	6 th	10 ⁷	/	/

[0054] ELISA results of single colonies identified after 3 and 4 rounds of selection are shown in Tables 2-4 below. Two clones were of note: “1A12” (plate 1, row A, column 12) and “1E9” (plate 1, row E, column 9).

TABLE 2

plate 1													
	3 rounds						4 rounds						
	VASA peptide												
	1	2	3	4	5	6	7	8	9	10	11	12	
A.	0.062	0.061	0.057	0.063	0.065	0.092	0.059	0.059	0.059	0.060	0.059	0.550	
B.	0.055	0.058	0.056	0.056	0.064	0.073	0.060	0.057	0.060	0.060	0.058	0.063	0.059
C.	0.065	0.058	0.060	0.063	0.069	0.072	0.069	0.063	0.066	0.061	0.070	0.063	
D.	0.072	0.064	0.067	0.066	0.061	0.062	0.069	0.069	0.070	0.070	0.070	0.117	0.071
E.	0.778	0.058	0.055	0.071	0.056	0.059	0.057	0.056	0.458	0.064	0.060	0.059	
F.	0.057	0.059	0.059	0.060	0.059	0.062	0.063	0.057	0.059	0.057	0.059	0.056	
G.	0.058	0.055	0.056	0.082	0.061	0.066	0.061	0.057	0.056	0.058	0.068	0.055	
H.	0.044	0.058	0.058	0.056	0.053	0.096	0.056	0.052	0.056	0.054	0.054	0.056	
	non-relevant peptide												
	1	2	3	4	5	6	7	8	9	10	11	12	
A.	0.085	0.063	0.062	0.069	0.056	0.089	0.054	0.059	0.056	0.057	0.057	0.061	
B.	0.062	0.053	0.054	0.06	0.09	0.066	0.063	0.054	0.054	0.058	0.058	0.062	
C.	0.064	0.063	0.071	0.069	0.069	0.067	0.062	0.06	0.057	0.062	0.064	0.057	
D.	0.094	0.063	0.067	0.069	0.069	0.067	0.071	0.067	0.067	0.066	0.135	0.061	
E.	0.078	0.058	0.059	0.116	0.055	0.057	0.054	0.064	0.061	0.054	0.056	0.059	
F.	0.062	0.056	0.056	0.056	0.055	0.064	0.063	0.057	0.062	0.056	0.054	0.058	
G.	0.057	0.06	0.059	0.066	0.056	0.064	0.057	0.057	0.057	0.055	0.077	0.055	
H.	0.061	0.066	0.061	0.054	0.058	0.111	0.057	0.054	0.057	0.058	0.052	0.054	

TABLE 3

plate 2-after 4 round of selection												
	VASA peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.052	0.045	0.053	0.045	0.051	0.045	0.046	0.044	0.049	0.044	0.045	0.050
B.	0.049	0.051	0.051	0.045	0.042	0.054	0.046	0.045	0.055	0.045	0.048	0.053
C.	0.048	0.047	0.048	0.054	0.051	0.047	0.047	0.045	0.047	0.052	0.051	0.055
D.	0.062	0.050	0.048	0.047	0.059	0.056	0.059	0.063	0.048	0.057	0.052	0.061
E.	0.047	0.042	0.042	0.045	0.051	0.041	0.047	0.042	0.044	0.052	0.050	0.054
F.	0.047	0.049	0.040	0.042	0.046	0.043	0.046	0.042	0.052	0.045	0.051	0.054
G.	0.047	0.052	0.045	0.041	0.039	0.051	0.048	0.049	0.052	0.043	0.054	0.050
H.	0.055	0.048	0.054	0.042	0.043	0.048	0.048	0.049	0.051	0.051	0.048	0.054
	non-relevant peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.047	0.053	0.050	0.042	0.053	0.053	0.041	0.043	0.042	0.053	0.053	0.054
B.	0.052	0.053	0.054	0.054	0.053	0.043	0.043	0.045	0.053	0.045	0.055	0.054
C.	0.052	0.047	0.054	0.053	0.055	0.045	0.045	0.043	0.053	0.055	0.057	0.053
D.	0.047	0.049	0.054	0.056	0.047	0.049	0.054	0.051	0.056	0.062	0.065	0.062
E.	0.052	0.045	0.042	0.045	0.041	0.051	0.040	0.047	0.041	0.056	0.053	0.054
F.	0.052	0.053	0.041	0.045	0.052	0.053	0.054	0.052	0.533	0.049	0.045	0.053
G.	0.051	0.053	0.049	0.050	0.051	0.043	0.049	0.052	0.053	0.053	0.054	0.051
H.	0.055	0.052	0.054	0.053	0.045	0.051	0.051	0.051	0.052	0.062	0.054	0.053

TABLE 4

plate 3-after 4 rounds of selection												
	VASA peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.074	0.052	0.058	0.076	0.052	0.063	0.052	0.055	0.040	0.052	0.054	0.072
B.	0.047	0.041	0.052	0.064	0.072	0.051	0.059	0.048	0.053	0.048	0.054	0.053
C.	0.051	0.042	0.042	0.044	0.053	0.056	0.052	0.048	0.044	0.048	0.060	0.056
D.	0.057	0.049	0.045	0.051	0.053	0.046	0.067	0.047	0.046	0.046	0.059	0.058
E.	0.054	0.046	0.042	0.126	0.041	0.047	0.051	0.040	0.042	0.043	0.048	0.073
F.	0.077	0.045	0.040	0.047	0.042	0.040	0.042	0.039	0.041	0.053	0.051	0.051
G.	0.178	0.056	0.044	0.041	0.051	0.050	0.055	0.042	0.042	0.051	0.044	0.052
H.	0.054	0.042	0.045	0.041	0.049	0.039	0.045	0.089	0.050	0.051	0.061	0.055
	non-relevant peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.050	0.056	0.055	0.049	0.053	0.055	0.051	0.059	0.051	0.044	0.047	0.054
B.	0.058	0.075	0.061	0.064	0.073	0.061	0.053	0.054	0.059	0.056	0.059	0.063
C.	0.076	0.056	0.053	0.054	0.056	0.053	0.053	0.053	0.057	0.063	0.049	0.061
D.	0.069	0.052	0.052	0.058	0.056	0.048	0.059	0.059	0.056	0.052	0.051	0.056
E.	0.047	0.056	0.050	0.118	0.063	0.067	0.052	0.053	0.054	0.053	0.056	0.054
F.	0.053	0.054	0.054	0.052	0.054	0.054	0.053	0.053	0.043	0.056	0.046	0.056
G.	0.063	0.056	0.054	0.045	0.045	0.049	0.050	0.053	0.053	0.052	0.055	0.053
H.	0.058	0.055	0.054	0.047	0.053	0.048	0.050	0.051	0.054	0.053	0.053	0.058

[0055] ELISA results of single colonies identified after 5 rounds of selection are shown in Tables 5-7 below. Clones of note included 1A11, 1B4, 1B7, 1D4, 1D5, 1E2, 1E3, 1F7, 1G3, 1G12, 2B8, 2C7, 2E11, 2F1, 2G8, 2G10, 2H9, 3B2, 3B5, 3B7, 3D11, 3E5, 3E12, 3F6 and 3H11.

TABLE 5

plate 1-after 5 rounds of selection												
	VASA peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.049	0.049	0.122	0.135	0.050	0.129	0.051	0.089	0.077	0.084	0.227	0.077
B.	0.051	0.197	0.056	0.212	0.067	0.099	0.280	0.109	0.122	0.094	0.049	0.053
C.	0.181	0.168	0.062	0.059	0.105	0.051	0.127	0.098	0.101	0.093	0.061	0.080
D.	0.057	0.186	0.143	0.408	0.527	0.057	0.178	0.061	0.124	0.060	0.061	0.077
E.	0.159	0.342	0.230	0.046	0.047	0.042	0.120	0.119	0.053	0.119	0.126	0.064
F.	0.160	0.177	0.160	0.086	0.048	0.134	0.248	0.053	0.079	0.054	0.159	0.052
G.	0.167	0.119	0.246	0.085	0.049	0.050	0.050	0.052	0.050	0.102	0.053	0.458
H.	0.126	0.136	0.096	0.050	0.048	0.049	0.060	0.049	0.058	0.104	0.066	0.052
	non-relevant peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.053	0.054	0.051	0.052	0.053	0.054	0.054	0.050	0.051	0.044	0.050	0.052
B.	0.056	0.054	0.053	0.053	0.052	0.052	0.062	0.053	0.052	0.053	0.054	0.053
C.	0.056	0.055	0.056	0.056	0.056	0.053	0.053	0.052	0.052	0.051	0.054	0.053
D.	0.060	0.060	0.060	0.057	0.065	0.059	0.058	0.061	0.052	0.056	0.057	0.055
E.	0.052	0.083	0.051	0.053	0.043	0.043	0.042	0.039	0.043	0.050	0.053	0.057
F.	0.052	0.052	0.050	0.050	0.041	0.040	0.048	0.043	0.050	0.053	0.052	0.052
G.	0.051	0.051	0.048	0.049	0.052	0.043	0.054	0.046	0.052	0.051	0.053	0.061
H.	0.052	0.048	0.046	0.049	0.044	0.050	0.050	0.049	0.049	0.051	0.051	0.052

TABLE 6

plate 2-after 5 rounds of selection												
	VASA peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.075	0.051	0.067	0.050	0.049	0.069	0.150	0.094	0.081	0.050	0.043	0.103
B.	0.136	0.054	0.107	0.075	0.059	0.052	0.120	0.318	0.159	0.095	0.152	0.052
C.	0.103	0.056	0.055	0.052	0.140	0.053	0.210	0.056	0.116	0.054	0.140	0.114
D.	0.098	0.141	0.058	0.114	0.104	0.057	0.070	0.077	0.079	0.049	0.138	0.054
E.	0.071	0.065	0.058	0.077	0.044	0.050	0.121	0.051	0.050	0.049	0.212	0.083
F.	0.210	0.051	0.046	0.110	0.043	0.063	0.043	0.056	0.052	0.057	0.051	0.062
G.	0.054	0.078	0.064	0.060	0.053	0.051	0.054	0.475	0.055	0.272	0.076	0.061

H.	0.050	0.050	0.050	0.054	0.050	0.054	0.051	0.050	0.290	0.055	0.061	0.056
non-relevant peptide												
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.040	0.041	0.044	0.041	0.040	0.048	0.046	0.047	0.040	0.045	0.044	0.045
B.	0.039	0.052	0.039	0.047	0.042	0.050	0.052	0.060	0.053	0.042	0.045	0.043
C.	0.036	0.043	0.051	0.041	0.042	0.051	0.053	0.062	0.052	0.053	0.050	0.040
D.	0.047	0.055	0.048	0.046	0.047	0.051	0.049	0.058	0.048	0.052	0.054	0.052
E.	0.051	0.051	0.040	0.039	0.043	0.041	0.040	0.040	0.040	0.043	0.067	0.046
F.	0.054	0.051	0.046	0.045	0.47	0.040	0.043	0.050	0.043	0.049	0.048	0.040
G.	0.038	0.050	0.047	0.040	0.039	0.039	0.045	0.060	0.041	0.048	0.050	0.044
H.	0.039	0.058	0.039	0.040	0.049	0.048	0.050	0.049	0.058	0.048	0.044	0.049

TABLE 7

plate 3-after 5 rounds of selection												
	VASA peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.047	0.122	0.105	0.176	0.177	0.102	0.040	0.164	0.104	0.109	0.169	0.081
B.	0.048	0.218	0.094	0.054	0.314	0.155	0.287	0.146	0.052	0.166	0.054	0.054
C.	0.199	0.059	0.052	0.105	0.060	0.054	0.118	0.152	0.054	0.145	0.055	0.053
D.	0.053	0.096	0.066	0.056	0.058	0.077	0.055	0.048	0.196	0.155	0.259	0.133
E.	0.139	0.052	0.052	0.046	0.471	0.089	0.199	0.052	0.049	0.042	0.173	0.244
F.	0.055	0.051	0.068	0.046	0.093	0.412	0.083	0.041	0.129	0.052	0.053	0.053
G.	0.101	0.056	0.058	0.039	0.051	0.050	0.075	0.046	0.042	0.044	0.070	0.052
H.	0.135	0.083	0.062	0.052	0.052	0.050	0.056	0.071	0.073	0.094	0.200	0.050
	non-relevant peptide											
	1	2	3	4	5	6	7	8	9	10	11	12
A.	0.055	0.056	0.053	0.051	0.054	0.056	0.054	0.45	0.049	0.053	0.055	0.053
B.	0.057	0.057	0.054	0.055	0.059	0.056	0.056	0.044	0.058	0.052	0.054	0.055
C.	0.057	0.055	0.056	0.054	0.049	0.052	0.043	0.052	0.055	0.055	0.050	0.055
D.	0.060	0.062	0.059	0.058	0.061	0.058	0.057	0.047	0.059	0.058	0.061	0.059
E.	0.056	0.045	0.048	0.055	0.071	0.048	0.046	0.043	0.048	0.056	0.056	0.059
F.	0.054	0.045	0.055	0.047	0.053	0.070	0.044	0.052	0.053	0.053	0.054	0.055
G.	0.052	0.055	0.049	0.049	0.041	0.047	0.044	0.046	0.054	0.053	0.053	0.051
H.	0.053	0.052	0.057	0.041	0.046	0.044	0.051	0.051	0.052	0.052	0.048	0.050

[0056] Clones shown in bold were PCR amplified.

Conversion to scFv-Fc fusion and expression in mammalian cells

[0057] After 5 rounds of panning, DNA digestion patterns showed that many clones from the 5th round of panning were the same, indicating that additional rounds of selection and ELISA analysis were not needed.

[0058] Two unique clones (1A12, 1E9) were selected for conversion to scFv-Fc fusions for expression in mammalian cells and for ELISA and FACS analysis. Figure 5A shows dose response binding curves that indicated that 1E9 had an EC50 of 0.02779 nM and 1A12 had an EC50 of 0.2156 nM. In addition, Figure 5B shows the results of ELISA assays with the V1 and V2 VASA peptides which suggest that 1E9 binds the same epitope as the commercially available rabbit polyclonal antibody (AB13840, Abcam plc, Cambridge, UK).

[0059] Two different forms of the 1E9 antibody were compared: IgG and scFv-Fc. As shown in Figure 6A, 1E9 IgG had an EC50 of 0.08919 nM and the 1E9 scFv-Fc had an EC50 of 0.3072 nM. In addition, as shown in Figure 6B, both forms were specific towards the VASA-1 epitope.

Synthetic Antibody Gene Production

[0060] The following steps were employed to produce synthetic antibody genes:

[0061] (1) Subtype determination of hybridoma antibodies. The IgG subtypes of the hybridoma antibodies were determined using commercially available kits according to manufacturer's protocols (e.g., Mouse Monoclonal Antibody Isotyping Kit, Catalog No. MMT1, AbDSerotech, Kidlington, UK). Figure 8 shows the result of subtyping analysis for anti-VASA antibodies from eight hybridomas (2M1/1L20, 2M1/1J20, 1M1/1C9, 2M1/1N3, 2M1/1K23, 1M1/1L5 and 2M1/2K4). All of the antibodies were IgG1, IgG2a or IgG2b.

[0062] (2) Degenerate primer synthesis. Based on the subtype information for the eight hybridoma antibodies tested, degenerate primers for mouse IgG VH and VL were designed using sequence information from a mouse IgG database (*i.e.*, the International Immunogenetics Information System® or IMGT database; see Lefranc *et al.* (2003), *Leukemia* 17:260-266, and Alamyar *et al.* (2012), *Methods Mol. Biol.* 2012;882:569-604). Ten degenerate forward primers were designed and synthesized for the VH chain and ten for the VL chain (9 for kappa and one for lambda chains). In addition, two degenerate reverse primers for the VH chain (one for the IgG1 and IgG2b subtypes, and one for the IgG2a subtype) and five for the VL chain (four for kappa and one for lambda chains) were designed and synthesized.

[0063] (3) RNA extraction, amplification, cloning and sequencing. RNA was extracted from hybridoma cells by standard techniques, first strand cDNA synthesis was performed by standard techniques using gene-specific and oligo(dT) primers, and the cDNA was amplified using gene-specific primers. The amplified DNA was then ligated into a commercially

available bacterial cloning vector (pMD18-T, Sino Biological, Inc., Beijing, China). Standard methodologies were conducted to transform the ligation products into *E. coli* DH5a, and to sequence positive clones.

Antibody Sequence Analyses

[0064] Clones producing potentially useful anti-Vasa antibodies were DNA sequenced and the corresponding amino acid sequences were deduced. Sequences are disclosed for eight antibodies derived from the hybridomas described above (*i.e.*, 1N23, 1K23, 2K4, 1C9, 1J20, 1L20, 1K3, 1L5), four additional antibodies derived from hybridomas produced under contract (*i.e.*, CTA4/5, CTB4/11, CTC2/6, CTD2/6) and two antibodies derived from phage display (*i.e.*, 1A12 and 1E9).

Variable Light Chain Sequences

[0065] VL of 1N23. Positive VL clones from the 1N23 hybridoma were sequenced and six were found to encode functional VL chains. These six clones were designated 1N23VL5-5, 1N23VL5-8_0816, 1N23VL1-8, 1N23VL1-2_0820, 1N23VL1-4_0820 and 1N23VL1-2.

[0066] VL of 1K23. Positive VL clones from the 1K23 hybridoma were sequenced and four were found to encode functional VL chains. These four clones were designated 1K23VL2-5, 1K23VL2-6, 1K23VL2-8_0822 and 1K23VL2-3_0829.

[0067] VL of 2K4. Positive VL clones from the 2K4 hybridoma were sequenced and eight were found to encode functional VL chains. These eight clones were designated 2K4VL1-3_0820, 2K4VL1-4, 2K4VL1-1, 2K4VL1-6_0820, 2K4VL2-5_0816, 2K4VL2-4, 2K4VL2-6_0816 and 2K4VL2-5.

[0068] VL of 1C9. Positive VL clones from the 1C9 hybridoma were sequenced and three were found to encode functional VL chains. These three clones were designated 1C9VL2-4, 1C9VL2-6 and 1C9VL2-3_0816.

[0069] VL of 1J20. Positive VL clones from the 1J20 hybridoma were sequenced and three were found to encode functional VL chains. These three clones were designated 1J20VL5-2_0907, 1J20VL5-6_0907 and 1J20VL4-3_0907.

[0070] VL of 1L20. Positive VL clones from the 1L20 hybridoma were sequenced and one was found to encode a functional VL chain. That clone was designated 1L20VL5-0912_091.

[0071] VL of 1K3. Positive VL clones from the 1K3 hybridoma were sequenced and four were found to encode functional VL chains. These four clones were designated 1K3VL2-5, 1K3VL2-5, 1K3VL2-3 and 1K3VL2-4.

[0072] VL of 1L5. Positive VL clones from the 1L5 hybridoma were sequenced and two were found to encode functional VL chains. These two clones were designated 1L5VL2-4 and 1L5VL3-1.

[0073] Additional VLs. VL sequences were obtained for four additional hybridoma antibodies designated CTA4_VL, CTB4_VL, CTC6_VL, CTD6_VL.

[0074] VL Sequence Alignments. Alignments of all of the VL sequences described above are shown in Figure 9. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.

[0075] Unique VL CDR Sequences. Alignments of the unique CDR sequences of the VLs of Figure 9 are shown in Figure 11. Of the 34 VL sequences, there are only 5 unique CDR1 sequences, 6 unique CDR2 sequences and 8 unique CDR3 sequences, as shown in Figure 11.

[0076] VL CDR Consensus Sequences. Based on the sequences disclosed in Figure 11, as well as structure/function characteristics of the naturally occurring amino acids, consensus sequences for the VL CDRs can be determined.

[0077] One consensus sequence is VL CDR1 Motif 1:

X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ X₁₀ X₁₁ (SEQ ID NO:132)

where X₁ is Q, N, K, R, S or T; X₂ is S, T, C, N or Q; X₃ is I, L, V, M or A; X₄ is V, L, I, M, A or absent; X₅ is H, K, R or absent; X₆ is S, T, C or absent; X₇ is N, Q or absent; X₈ is G, A or absent; X₉ is N or Q; X₁₀ is T, S, C, N or Q; and X₁₁ is Y, F or W. In some embodiments, X₁ is limited to Q, K or S; and/or X₂ is limited to S or N; and/or X₃ is limited to I or L; and/or X₄ is limited to V, L or absent; and/or X₅ is limited to H or absent; and/or X₆ is limited to S or absent; and/or X₇ is limited to N or absent; and/or X₈ is limited to G or absent; and/or X₉ is limited to N; and/or X₁₀ is limited to T, S or N; and/or X₁₁ is limited to Y or F. In some embodiments, the subsequence X₁ X₂ X₃ is limited to Q N I; in some embodiments, the subsequence X₁ X₂ X₃ is limited to Q S L; and in some embodiments, the subsequence X₁ X₂ X₃ is limited to K S L. In addition, in some embodiments, when X₁ X₂ X₃ is Q S L or Q N I, then X₄ is V; whereas in other embodiments, when X₁ X₂ X₃ is K S L, then X₄ is L. In some embodiments, when X₉ X₁₀ is N T, then X₁₁ is Y.

[0078] Noting in particular that the VL CDR1 sequences of SEQ ID NOs: 86-88 are quite distinct from the others in Figure 11, an alternative consensus sequence is VL CDR1 Motif 2:

$X_1 X_2 X_3 X_4 X_5 X_6 X_7 X_8 X_9 X_{10} X_{11}$ (SEQ ID NO:133)

where X_1 is Q, N, K or R; X_2 is S, T, C, N or Q; X_3 is I, L, V, M or A; X_4 is V, L, I, M or A; X_5 is H, K or R; X_6 is S, T or C; X_7 is N or Q; X_8 is G or A; X_9 is N or Q; X_{10} is T, S or C; and X_{11} is Y, F or W. In some embodiments, X_1 is limited to Q or K; and/or X_2 is limited to S or N; and/or X_3 is limited to I or L; and/or X_4 is limited to V or L; and/or X_5 is limited to H; and/or X_6 is limited to S; and/or X_7 is limited to N; and/or X_8 is limited to G; and/or X_9 is limited to N; and/or X_{10} is limited to T; and/or X_{11} is limited to Y. In some embodiments, the subsequence $X_1 X_2 X_3$ is limited to Q N I; in some embodiments, the subsequence $X_1 X_2 X_3$ is limited to Q S L; and in some embodiments, the subsequence $X_1 X_2 X_3$ is limited to K S L. In addition, in some embodiments, when $X_1 X_2 X_3$ is Q S L or Q N I, then X_4 is V; whereas in other embodiments, when $X_1 X_2 X_3$ is K S L, then X_4 is L. In some embodiments, when $X_9 X_{10}$ is N T, then X_{11} is Y.

[0079] For the VL CDR2, one consensus sequence is VL CDR2 Motif 1:

$Y_1 Y_2 Y_3$ (SEQ ID NO: 134)

where Y_1 is K, R or H; Y_2 is V, I, L, M, A, T, S or C; and Y_3 is S, T, C, N or Q. In some embodiments, Y_2 is limited to V, I, M or T; and/or Y_3 is limited to S or N.

[0080] Noting in particular that the VL CDR2 sequences of SEQ ID NO: 94 is quite distinct from the others in Figure 11, an alternative consensus sequence is VL CDR2 Motif 2:

$Y_1 Y_2 Y_3$ (SEQ ID NO: 135)

where Y_1 is D or E; Y_2 is N or Q; and Y_3 is N or Q. In some embodiments, Y_1 is limited to D; and/or Y_2 is limited to N; and/or Y_3 is limited to N.

[0081] Similarly, noting that the VL CDR2 sequences of SEQ ID NO: 95 is quite distinct from the others in Figure 11, an alternative consensus sequence is VL CDR2 Motif 3:

$Y_1 Y_2 Y_3$ (SEQ ID NO: 136)

where Y_1 is Q or N; Y_2 is D or E; and Y_3 is K, R or H. In some embodiments, Y_1 is limited to Q; and/or Y_2 is limited to D; and/or Y_3 is limited to K.

[0082] For the VL CDR3, one consensus sequence is VL CDR3 Motif 1:

$Z_1 Z_2 Z_3 Z_4 Z_5 Z_6 Z_7 Z_8 Z_9 Z_{10}$ (SEQ ID NO: 137)

where Z_1 is S, T, C, F, Y, M, L, V, I or A; Z_2 is Q, N, S, T or C; Z_3 is S, T, C, G, A, H, K, R, Q, N, Y, F or W; Z_4 is A, G, S, T, C, L, I, V, M, D or E; Z_5 is H, K, R, E, D, S, T or C; Z_6 is

V, L, I, M, A, Y, F, W, S, T or C; Z₇ is P, S, T, C or absent; Z₈ is S, T, C or absent; Z₉ is W, P, L, I, V, M, A, F, or Y; and Z₁₀ is T, S, C, V, L, I, M, A. In some embodiments, Z₁ is limited to S, F, M or L; and/or Z₂ is limited to Q or S; and/or Z₃ is limited to S, G, H, Q or Y; and/or Z₄ is limited to A, S, T, L, or D; and/or Z₅ is limited to H, E, D or S; and/or Z₆ is limited to V, Y, F, or S; and/or Z₇ is limited to P, S or absent; and/or Z₈ is limited to S or absent; and/or Z₉ is limited to W, P, L or F; and/or Z₁₀ is limited to T or V.

[0083] Noting in particular that the VL CDR3 sequences of SEQ ID NOs: 96-98 have a positive charge at position Z₅ whereas the others in Figure 11 do not, an alternative consensus sequence is VL CDR3 Motif 2:

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀ (SEQ ID NO:138)

where Z₁ is S, T, C, F or Y; Z₂ is Q or N; Z₃ is S, T, C, G or A; Z₄ is A, G, S, T or C; Z₅ is H, K or R; Z₆ is V, L, I, M or A; Z₇ is P or absent; Z₈ is absent; Z₉ is W, P, L, I, V, M, A, F or Y; and Z₁₀ is T, S, or C. In some embodiments, Z₁ is limited to S or F; and/or Z₂ is limited to Q; and/or Z₃ is limited to S or G; and/or Z₄ is limited to A, S or T; and/or Z₅ is limited to H; and/or Z₆ is limited to V; and/or Z₇ is limited to P or absent; and/or Z₈ is limited to absent; and/or Z₉ is limited to W, P, L or F; and/or Z₁₀ is limited to T.

[0084] Noting in particular that the VL CDR3 sequences of SEQ ID NOs: 99-102 have a negative charge at position Z₅ whereas the others in Figure 11 do not, an alternative consensus sequence is VL CDR3 Motif 3:

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀ (SEQ ID NO:139)

where Z₁ is M, C, L, I, V, A; Z₂ is Q or N; Z₃ is H, K, R, Q, N, G, A, Y or F; Z₄ is L, I, V, M, A, D or E; Z₅ is E or D; Z₆ is Y or F; Z₇ is P; Z₈ is absent; Z₉ is W, P, L, I, V, M, A, F or Y; and Z₁₀ is T, S, or C. In some embodiments, Z₁ is limited to M or L,; and/or Z₂ is limited to Q; and/or Z₃ is limited to H, Q, G or Y; and/or Z₄ is limited to L or D; and/or Z₅ is limited to E or D; and/or Z₆ is limited to Y or F; and/or Z₇ is limited to P; and/or Z₈ is limited to absent; and/or Z₉ is limited to W, P, L or F; and/or Z₁₀ is limited to T.

[0085] Noting in particular that the VL CDR3 sequence of SEQ ID NO: 103 is quite distinct from the others in Figure 11, an alternative consensus sequence is VL CDR3 Motif 4:

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀ (SEQ ID NO:140)

where Z₁ is S, T or C; Z₂ is S, T or C; Z₃ is Y or F; Z₄ is T, S, or C; Z₅ is S, T or C; Z₆ is S, T or C; Z₇ is S, T or C; Z₈ is S, T or C; Z₉ is W, P, F or Y; and Z₁₀ is V, L, I, M, A, T, S or C. In some embodiments, Z₁ is limited to S or T; and/or Z₂ is limited to S or T; and/or Z₃ is

limited to Y; and/or Z₄ is limited to T or S; and/or Z₅ is limited to S or T; and/or Z₆ is limited to S or T; and/or Z₇ is limited to S or T; and/or Z₈ is limited to S or T; and/or Z₉ is limited to W, P or F; and/or Z₁₀ is limited to V, L, I, T or S. In some embodiments, Z₁ is limited to S; and/or Z₂ is limited to S; and/or Z₃ is limited to Y; and/or Z₄ is limited to T; and/or Z₅ is limited to S; and/or Z₆ is limited to S; and/or Z₇ is limited to S; and/or Z₈ is limited to S; and/or Z₉ is limited to W; and/or Z₁₀ is limited to V.

[0086] Finally, noting in particular that the VL CDR3 sequence of SEQ ID NO: 104 is quite distinct from the others in Figure 11, an alternative consensus sequence is VL CDR3 Motif 5:

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀ (SEQ ID NO:141)

where Z₁ is Q or N; Z₂ is A or G; Z₃ is W, Y or F; Z₄ is D or E; Z₅ is S, T or C; Z₆ is R, K or H; Z₇ is T, S or C; Z₈ is V, I, L, M or A; Z₉ is V, I, L, M or A; and Z₁₀ is I, L, V, M or A. In some embodiments, Z₁ is limited to Q; and/or Z₂ is limited to A; and/or Z₃ is limited to W; and/or Z₄ is limited to D; Z₅ is limited to S; and/or Z₆ is limited to R; and/or Z₇ is limited to T; and/or Z₈ is limited to V; and/or Z₉ is limited to V; and/or Z₁₀ is limited to I.

Variable Heavy Chain Sequences

[0087] VH of 1N23. Positive VH clones from the 1N23 hybridoma were sequenced and all four were found to encode functional VH chains. These four clones were designated 1N23VH3-5, 1N23VH3-7, 1N23VH2-1 and 1N23VH1-5.

[0088] VH of 1K23. Positive VH clones from the 1K23 hybridoma were sequenced and six were found to encode functional VH chains. These six clones were designated 1K23VH2-1_0910, 1K23VH1-4_0907, 1K23VH1-10_0907, 1K23VH8-4_0907, 1K23VH8-5_0907 and 1K23VH8-9_0907.

[0089] VH of 2K4. Positive VH clones from the 2K4 hybridoma were sequenced and four were found to encode functional VH chains. These four clones were designated 2K4VH3-8, 2K4VH2-8, 2K4VH1-1 and 2K4VH1-4.

[0090] VH of 1C9. Positive VH clones from the 1C9 hybridoma were sequenced and eight were found to encode functional VL chains. These eight clones included four unique sequences which are designated 1C9VH2-404-8_1024, 1C9VH2-405-12_1024, 1C9VH2-411-1_1024 and 1C9VH2-406-4_1024.

[0091] VH of 1J20. Positive VH clones from the 1J20 hybridoma were sequenced and two were found to encode functional VH chains. These two clones were designated 1J20VH1-7_0910 and 1J20VH1-1-6_0829.

[0092] VH of 1L20. Positive VH clones from the 1L20 hybridoma were sequenced and three were found to encode functional VH chains. These three clones were designated 1L20VH2-3_0903, 1L20VH2-1_0907 and 1L20VH2-3_0910.

[0093] VH of 1K3. Positive VH clones from the 1K3 hybridoma were sequenced and five were found to encode functional VH chains. These five clones were designated 1K3VH6-7, 1K3VH6-8_0816, 1K3VH3-4, 1K3VH3-4 and 1K3VH3-3_0816.

[0094] VH of 1L5. Positive VH clones from the 1L5 hybridoma were sequenced and nine were found to encode functional VH chains. These nine clones were designated 1L5VH003-5-8_0907, 1L5VH003-6-3_0907, 1L5VH001-7-6_0907, 1L5VH001-6-5_0907, 1L5VH001-6-11_0907, 1L5VH003-6-2_0910, 1L5VH001-6-12_0907, 1L5VH003-3-4_0907 and 1L5VH003-3-8_0907.

[0095] Additional VHs. VH sequences were obtained for four additional hybridoma antibodies designated CTA5_VH, CTB11_VH, CTC2_VH, CTD2_VH.

[0096] VH Sequence Alignments. Alignments of all of the VH sequences described above are shown in Figure 10. The figure indicates the approximate locations of the three CDR regions (bold, underscore) and the SEQ ID NO corresponding to each sequence.

[0097] Unique VH CDR Sequences. Alignments of the unique CDR sequences of the VHs of Figure 10 are shown in Figure 12. Of the 43 VH sequences, there are only 8 unique CDR1 sequences, 9 unique CDR2 sequences and 10 unique CDR3 sequences, as shown in Figure 12.

[0098] VH CDR Consensus Sequences. Based on the sequences disclosed in Figure 12, as well as structure/function characteristics of the naturally occurring amino acids, consensus sequences for the VH CDRs can be determined.

[0099] For the VH CDR1, one consensus sequence is VH CDR1 Motif 1:

X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ (SEQ ID NO:142)

where X₁ is G or A; X₂ is Y, F, W, D or E; X₃ is T, S, C or M; X₄ is F, Y, W, V, L, I, M or A; X₅ is T, S, C, N, or Q; X₆ is S, T, C, A or G; X₇ is Y, F, W, N, Q, G or A; and X₈ is W, A, G, Y or F. In some embodiments, X₁ is limited to G; and/or X₂ is limited to Y, F or D; and/or X₃ is limited to T or S; and/or X₄ is limited to F or V; and/or X₅ is limited to T, S or N; and/or

X_6 is limited to S, T or A; and/or X_7 is limited to Y, F, N or G; and/or X_8 is limited to W, A or Y. In some embodiments, the subsequence $X_1 X_2 X_3$ is limited to G Y T; and in some embodiments, the subsequence $X_1 X_2 X_3$ is limited to G F T. In addition, in some embodiments, the subsequence $X_1 X_7 X_8$ is limited to S Y W.

[0100] Noting in particular that the VH CDR1 sequence of SEQ ID NOs: 109-110 and 112 are quite distinct from the others in Figure 12, an alternative consensus sequence is VH CDR1 Motif 2:

$X_1 X_2 X_3 X_4 X_5 X_6 X_7 X_8$ (SEQ ID NO: 143)

where X_1 is G or A; X_2 is Y, F or W; X_3 is T, S, C or M; X_4 is F, Y or W; X_5 is T, S or C; X_6 is S, T or C; X_7 is Y, F or W; and X_8 is W. In some embodiments, X_1 is limited to G; and/or X_2 is limited to Y or F; and/or X_3 is limited to T or S; and/or X_4 is limited to F; and/or X_5 is limited to T or S; and/or X_6 is limited to S or T; and/or X_7 is limited to Y or F; and/or X_8 is limited to W. In some embodiments, the subsequence $X_1 X_2 X_3$ is limited to G Y T; and in some embodiments, the subsequence $X_1 X_2 X_3$ is limited to G F T. In addition, in some embodiments, the subsequence $X_1 X_7 X_8$ is limited to S Y W.

[0101] For the VH CDR2, one consensus sequence is VH CDR2 Motif 1:

$Y_1 Y_2 Y_3 Y_4 Y_5 Y_6 Y_7 Y_8 Y_9 Y_{10}$ (SEQ ID NO: 144)

where Y_1 is I, L, V, M or A; Y_2 is Y, F, H, R, K, S or T; Y_3 is P, S, T, Y, F, R, K or H; Y_4 is G, A, S, T, K, R, H, D or E; Y_5 is T, S or absent; Y_6 is R, K, H or absent; Y_7 is N, Q, D, E, G, A or absent; Y_8 is G, A, S, T, Y or F; Y_9 is D, E, A, G, N or Q; and Y_{10} is T, S, I, L, V, M, A, K, R or H. In some embodiments, Y_1 is limited to I; and/or Y_2 is limited to Y, H, R, K or S; and/or Y_3 is limited to P, S, Y or R; and/or Y_4 is limited to G, S, K or D; and/or Y_5 is limited to T or absent; and/or Y_6 is limited to R or absent; and/or Y_7 is limited to N, D, G or absent; and/or Y_8 is limited to G, A, S or Y; and/or Y_9 is limited to D, E, A or N; and/or Y_{10} is limited to T, I or K.

[0102] Noting in particular that the VH CDR2 sequence of SEQ ID NO: 120-121 are quite distinct from the others in Figure 12, an alternative consensus sequence is VH CDR2 Motif 2:

$Y_1 Y_2 Y_3 Y_4 Y_5 Y_6 Y_7 Y_8 Y_9 Y_{10}$ (SEQ ID NO:145)

where Y_1 is I, L, V, M or A; Y_2 is Y, F, H, R, K, S or T; Y_3 is P, S, T, Y or F; Y_4 is G, A, S, T, K, R or H; Y_5 is T, S or absent; Y_6 is R, K, H or absent; Y_7 is N, Q, D, E or absent; Y_8 is G, A, S, T, Y or F; Y_9 is D, E, A, G, N or Q; and Y_{10} is T, S, I, L, V, M or A. In some

embodiments, Y₁ is limited to I; and/or Y₂ is limited to Y, H, R or S; and/or Y₃ is limited to P, S or Y; and/or Y₄ is limited to G, S or K; and/or Y₅ is limited to T or absent; and/or Y₆ is limited to R or absent; and/or Y₇ is limited to N, D or absent; and/or Y₈ is limited to G, A, S or Y; and/or Y₉ is limited to D, E, A or N; and/or Y₁₀ is limited to T or I.

[0103] For the VH CDR3, one consensus sequence is VH CDR3 Motif 1:

Z₁ Z₂ Z₃ Z₄ Z₅ Z₆ Z₇ Z₈ Z₉ Z₁₀ Z₁₁ Z₁₂ Z₁₃ Z₁₄ Z₁₅ (SEQ ID NO:146)

where Z₁ is A, G, V, L, I or M; Z₂ is R, K, H, C or M; Z₃ is G, A, R, K, H, S, T, Y, F, W, D, E or absent; Z₄ is Y, F, W, N, Q, G, A, R, K, H or absent; Z₅ is S, T, N, Q, E, D or absent; Z₆ is D, E or absent; Z₇ is L, I, V, M, A, S, T or absent; Z₈ is L, I, V, M, A or absent; Z₉ is G, A, R, K, H or absent; Z₁₀ is I, L, V, M, A, N, Q, R, K, H or absent; Z₁₁ is A, M, F, Y, W, S, T, G or absent; Z₁₂ is W, Y, F, A, G or absent; Z₁₃ is F, Y, W, G, A, M or C; Z₁₄ is A, G, M, D, E, W, Y or F; and Z₁₅ is Y, F, W, G, A or V. In some embodiments, Z₁ is limited to A or V; and/or Z₂ is limited to R, K or C; and/or Z₃ is limited to G, R, S, Y, D or absent; and/or Z₄ is limited to Y, N, G, R or absent; and/or Z₅ is limited to S, N, E or absent; and/or Z₆ is limited to D or absent; and/or Z₇ is limited to L, S or absent; and/or Z₈ is limited to L or absent; and/or Z₉ is limited to G, R or absent; and/or Z₁₀ is limited to I, N, R, L or absent; and/or Z₁₁ is limited to A, F, S, G or absent; and/or Z₁₂ is limited to W, Y, A or absent; and/or Z₁₃ is limited to F, Y, G or M; and/or Z₁₄ is limited to A, D, W or Y; and/or Z₁₅ is limited to Y, F, W or G.

[0104] Although the disclosed subject matter has been described and illustrated in the foregoing exemplary embodiments, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the details of implementation of the disclosed subject matter may be made without departing from the spirit and scope of the disclosed subject matter, which is limited only by the claims which follow.

CLAIMS

We claim:

1. An antibody that specifically binds to a human VASA protein comprising:
an immunoglobulin heavy chain and an immunoglobulin light chain,
wherein the variable region of said light chain comprises:
 - (i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 83-88;
 - (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 89-95; and/or
 - (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 96-104.
2. An antibody that specifically binds to a human VASA protein comprising:
an immunoglobulin heavy chain and an immunoglobulin light chain,
wherein the variable region of said heavy chain comprises:
 - (i) a CDR1 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-112;
 - (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 113-121; and/or
 - (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 122-131.
3. An antibody that specifically binds to a human VASA protein comprising:
an immunoglobulin heavy chain and an immunoglobulin light chain,
wherein the variable region of said light chain comprises:

- (i) a CDR1 region comprising an amino acid sequence selected from the group consisting of VL CDR1 Motifs 1-2
- (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of VL CDR2 Motifs 1-3; and/or
- (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of VL CDR3 Motifs 1-5.

4. An antibody that specifically binds to a human VASA protein comprising:
an immunoglobulin heavy chain and an immunoglobulin light chain,
wherein the variable region of said heavy chain comprises:

- (i) a CDR1 region comprising an amino acid sequence selected from the group consisting of VH CDR1 Motifs 1-2;
- (ii) a CDR2 region comprising an amino acid sequence selected from the group consisting of VL CDR2 Motifs 1-2; and/or
- (iii) a CDR3 region comprising an amino acid sequence selected from the group consisting of VL CDR3 Motif 1.

5. A antibody preparation comprising an antibody of any one of claims 1-4.

6. The antibody preparation of claim 5 wherein said preparation is a monoclonal antibody preparation.

7. The antibody preparation of claim 5 wherein said preparation is a mixture of at least two monoclonal antibody preparations.

8. An isolated nucleic acid molecule encoding an heavy chain or light chain of any one of claims 1-4.

9. The isolated nucleic acid of claim 8 wherein said nucleic acid is selected from the group consisting of a cloning vector, an expression vector, a heterologous recombination vector and a viral integration vector.
10. A cell transformed with a nucleic acid of any one of claims 8-9.
11. The cell of claim 10 wherein said cell is a mammalian cell.
12. The cell of claim 11 wherein said cell is a rodent cell.
13. The cell of claim 11 wherein said cell is a CHO cell.
14. The cell of claim 11 wherein said cell is a human cell.
15. A method of isolating a cell expressing a VASA protein comprising:
 - (a) obtaining a population of cells;
 - (b) contacting the population of cells with a multiplicity of antibodies of any one of claims 1-4; and
 - (c) separating cells in the population that specifically bind the antibodies from cells in the population that do not specifically bind the antibodies.
16. The method of claim 15 wherein the cells are separated by fluorescence activated cell sorting.
17. The method of claim 15 wherein the cells are separated using an immobilized secondary antibody by fluorescence activated cell sorting.

1/15

Human VASA Amino Acid Sequence
 (Accession: NP_077726; SEQ ID NO: 1))

1 mgdedweaei nphmssyvpi fekdrysgen qdnfnrtpas ssemddgpsr rchfmksgfa
 61 sgrnfgnrda gecnkrdnts tmqgfvqks fgnrgfsnsr fedgdssqfw ressndcedn
 121 ptrnrgfskr ggyrdgnse asgpyrrggr gsfrgcrggf glgspnnld pdecmqrtgg
 181 lfqsrrpvls gtngdtsqs rsgsgsergg ykglnneevit gsgknswkse aeggessdtq
 241 gpkvtyippp ppededsifa hyqtginfk ydtilvevsg hdappaitf eanlcqtl
 301 nniakagytk ltpvqkysip iilagrnlma caqtgsgktaa flpilahm mhgditasrf
 361 kelqepecii vaptrelvnq iylearkfsf gtcvravviy ggtqlghsir qivqgcnilc
 421 atpgrlmdii qkekiglkqi kylvldeadr mldmgfpem kkliscpgmp skeqrqtlmf
 481 satfpeeigr laaeflknsny lfvavggvqg acrdvqqtvl qvgqfskrek lveilrnigd
 541 ertmvfvetk kkadfiatfl cqekisttsi hgdrere qalgdfrfqk cpvlvatsva
 601 argldienvq hvinfldpst ideyvhrigr tgrcgntgra isffdlesdn hlaqplvkvl
 661 tdaqqdvpaw leeiafstyi pgfsgstrgn vfasvdtrkg kstlntagfs ssqapnpvdd
 721 eswd

FIG. 1

Mouse VASA Homolog Amino Acid Sequence
 (Accession: NP_001139357, SEQ ID NO: 2))

1 mgdedweaei lkphvssyvp vfekdkyssg angdtfnrts assemedgps grddfmrsqf
 61 psgrlsgsrda igesskkent sttggfgrgk gfgnrgflnn kfeegdssqf wkesnndced
 121 nqtrsrgfsk rggcqdgnnds easgpfrgg rgsfrgcrgg fglgrpnses dqdqgtqrgg
 181 glfgsrkpaa sdsngdtyq srsgsrggy kglneevvtg sgknswkset eggessdsqg
 241 pkvtyipppp pededsifah yqtginfky dtilvevsgh dappaitfe eanlcqtl
 301 niakagtykl tpvqkysipi vlagrnlmac aqtgsgktaa flpilahm rdgidasrfk
 361 elqepeciiv aptrelinqi ylearkfsf gtcvravviy gtfqfghsvrq ivqgenilca
 421 tpgrlmdiiig kekiglkqv ylvldeadrm ldmgfpemk klliscpgmpks keqrqtl
 481 atfpeeigr agdflkssyl fvavggvqg acrdvqqtvl vqgqfskrek lveilrnigde
 541 rtmvfvetkk kadfiatflc qekisttsih gdreqrereq algdfrcgkc pvlvatsvaa
 601 rgldienvqh vinfldpstideyvhrigr tgrcgntgrai sffdtdsdnh laqplvkvl
 661 daqqdvpawl eeiiafstyvp psfssstrgg avfasvdtrk nyqgkhtlnt agisssqapn
 721 pvddeeswd

FIG. 2

Human ...nvfasvdtrk gkstln>tagfsssqapnpvddeswd
 (SEQ ID NO: 1 residues 690-724)

Mouse ...avfasvdtrknyqgkhtln>tagisssqapnpvddeswd
 (SEQ ID NO: 2 residues 691-728)

FIG. 3




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B

5/15





FIG. 7A




	1E9-lambda	2M1/1K3	2M1/1K23	2M1/1L5
Best-fit values				
BOTTOM	0.1822	0.09026	0.1057	0.08715
TOP	1.007	1.509	1.326	1.154
LOGEC50	-0.8650	0.09294	-0.2333	-0.2855
HILLSLOPE	1.763	1.072	1.338	1.258
EC50	0.1365	1.239	0.5844	0.5182

FIG. 7B

6/15

Dose response binding of VASA antibodies



	1E9-lambda	2M1/2K4
Best-fit values		
BOTTOM	0.08445	0.1134
TOP	0.9319	1.437
LOGEC50	-0.5576	-0.3812
HILLSLOPE	0.8795	0.9339
EC50	0.2770	0.4157

FIG. 7C

Hybridoma subtype determination




FIG. 8

Light Chain Variable Region Sequence Alignments

SEQ ID NO.	CLONE NAME	CDR1	CDR2
3	1N23VL5-5	FIVMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
4	1N23VL5-8 0816	SIVMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
5	1N23VL1-8	LVLMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
6	1N23VL1-2 0820	SVLMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
7	1N23VL1-4 0820	YVLMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
8	1K23VL2-5	QVLMTQAPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
9	1N23VL1-2	RFQVQSTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
10	1K23VL2-6	VFVMTQAPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
11	1K23VL2-8 0822	LIVMTQAPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
12	1K23VL2-3 0829	SIVMTQAPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
13	2K4VL1-3 0820	SVLMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
14	2K4VL1-4	LIVMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
15	2K4VL1-1	LIVMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
16	2K4VL1-6 0820	LIVMTQTPISLPGDQASISCR-SSQSLVHSIGNITYLHWYIQLQPGQSPKLLIYKVSNRF	60
17	1C9VL2-4	LIVMTQAAAPSVPVTPGESVSIISCR-STKSLLLHSIGNITYLSWFLQRPQSPQLLIYRMSNLA	60
18	1C9VL2-6	YIVMTQAAAPSVPVTPGESVSIISCR-STKSLLLHSIGNITYLSWFLQRPQSPQLLIYRMSNLA	60
19	1C9VL2-3 0816	SGLMTQAAAPSVPVTPGESVSIISCR-STKSLLLHSIGNITYLSWFLQRPQSPQLLIYRMSNLA	60
20	2K4VL2-5 0816	PGLMTQAAAPSVPVTPGESVSIISCR-SSKSLLLHSIGNITYLYWFLQRPQSPQLLIYRMSNLA	60
21	2K4VL2-4	SLVMTQAAAPSVPVTPGESVSIISCR-SSKSLLLHSIGNITYLYWFLQRPQSPQLLIYRMSNLA	60
22	2K4VL2-6 0816	SIVMTQAAAPSVPVTPGESVSIISCR-SSKSLLLHSIGNITYLYWFLQRPQSPQLLIYRMSNLA	60
23	1J20VL5-2 0907	DIVMTQAAAPSVPVTPGESVSIISCR-SSKSLLLHSIGNITYLYWFLQRPQSPQLLIYRMSNLA	60

FIG. 9A

24	1J20VL5-6_0907	DIVMTQASAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
25	1J20VL4-3_0907	DGVMTQASAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
26	1L20VL5-0912_0917	DGVMTQASAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
27	1K3VL2_5	LIVMTQAAAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
28	1K3VL2_3	LIVMTQAAAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
29	1K3VL2_4	LIVMTQAAAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
30	2K4VL2_5	LIVMTQAAAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
31	1L5VL2_4	DIVMTQAAAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
32	1L5VL3_1	DIVMTQAAAPSVVTPGEVSISCR- <u>SSKSLLSEGMENTLYWFLQRPQSPOLLIVRMSNLA</u>	60
33	CTC6_VL	DIVMTQAAAPSVVTPGEVSISCR- <u>STKSLLSEGMENTLYWLLQRPQSPOLLIVHMSNLA</u>	60
34	CTD6_VL	DIVMTQAAAPSVVTPGEVSISCR- <u>STKSLLSEGMENTLYWLLQRPQSPOLLIVHMSNLA</u>	60
35	CTA4_VL	DIKMTQSPSSVFAASIGERVTTCK- <u>ASQ-----NINSETLWHEHQKPKGSPTTLIYRTRNLL</u>	55
36	CTB4_VL	DIKMTQSPSSVFAASIGERVTTCK- <u>ASQ-----NINSETLWHEHQKPKGSPTTLIYRTRNLL</u>	55
37	1E9_VL	SYVLTQ-PPSVSAAPGQKV TISCSSNT ----- <u>GNVYVSWYQQQLPCTAPKLLIYDNKRP</u>	56
38	1A12_VL	SYVLTQ-PPSVSVSPGQTAASVTCSSGD- <u>KL-----GNKYASWYQQKPGQSPVILVYQDKKRP</u>	55

FIG. 9A Cont.

Light Chain Variable Region Sequence Alignments (continued)

SEQ ID NO.	CLONE NAME	CDR3
3	IN2 3V15-5	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
4	IN2 3V15-8	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
5	IN2 3V11-8	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
6	IN2 3V11-2	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
7	IN2 3V11-4	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
8	1K2 3V12-5	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
9	1N2 3V11-2	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
10	1K2 3V12-6	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
11	1K2 3V12-8	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
12	1K2 3V12-3	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KKIGS</u> -112
13	2K4V11-3	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>SQSAHVP</u> -WTEGGT <u>KLEIK</u> -112
14	2K4V11-4	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>QFQSHV</u> --WTEGGT <u>KLEIK</u> -111
15	2K4V11-1	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>QFQSHV</u> --WTEGGT <u>KLEIK</u> -111
16	2K4V11-6	SGVPDRFSGSGSGTDE TI KINRVEAEDLGVVFC <u>QFQSHV</u> --WTEGGT <u>KLEIK</u> -111
17	1C9V12-4	SGVPDRFSGSGSGTAA <u>FTI</u> RISRVEAEDVGVVY <u>YCMQHLEYP</u> -LT <u>FGAGT</u> <u>KLEIK</u> -112
18	1C9V12-6	SGVPDRFSGSGSGTAA <u>FTI</u> RISRVEAEDVGVVY <u>YCMQHLEYP</u> -LT <u>FGAGT</u> <u>KLEIK</u> -112
19	1C9V12-3	SGVPDRFSGSGSGTAA <u>FTI</u> RISRVEAEDVGVVY <u>YCMQHLEYP</u> -LT <u>FGAGT</u> <u>KLEIK</u> -112
20	2K4V12-5	SGVPDRFSGSGSGTAA <u>FTI</u> RISRVEAEDVGVVY <u>YCMQHLEYP</u> -LT <u>FGAGT</u> <u>KLEIK</u> -112
21	2K4V12-4	SGVPDRFSGSGSGTAA <u>FTI</u> RISRVEAEDVGVVY <u>YCMQHLEYP</u> -LT <u>FGAGT</u> <u>KLEIK</u> -112

22	2K4VL2-6	0816	SGVPDRFSGSGSGTAAFTLIRISRVEAGDVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
23	1J20VL5-2	0907	SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
24	1J20VL5-6	0907	SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
25	1J20VL4-3	0907	SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
26	1L20VL5-0912	0917	SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
27	1K3VL2-5		SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
28	1K3VL2-3		SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
29	1K3VL2-4		SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
30	2K4VL2-5		SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
31	1L5VL2-4		SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-FI-FGGGTKLEIK-	112
32	1L5VL3-1		SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-FI-FGGGTKLEIK-	112
33	CTC6 VL		SGVPDRFSGSGSGTAAFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKGLK-	112
34	CTD6 VL		SGVPDRFSGSGSGTDFTLIRISRVEADVGIVYCMQHLEYP-LTFGAGTKLEIK-	112
35	CTA4 VL		DGVPSRFSGSGSGQDYSLTINSLEEDMGIYCYCLOYDDEP-LTFGAGTKVLEIK-	107
36	CTB4 VL		DGVPSRFSGSGSGQDYSLTINSLEEDMGIYCYCLOYDDEP-LTFGAGTKVLEIK-	107
37	1E9 VL		SGIPDRFSGSKSGTSATLIGTQGDEADYCSSYISSSSWFGGGTKVTVLG 110	
38	1A12 VL		SGIPERFSGSMNSGNATLTISGTQAMDEADYCOAQSRT-VVIGRGTKITVLG 108	

FIG. 9B Cont.

11/15

Heavy Chain Variable Region Sequence Alignments

SEQ ID NO.	CLONE NAME	CDR1		CDR2	
		CDR1	CDR2	CDR1	CDR2
39	1K3VH6-7	LVQIQQSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
40	1K3VH6-8 0816	LVQIQQSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
41	1K3VH3-8	IVQIKQSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
42	2K4VH3-8	IVQIKQSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
43	1K3VH3-4	IVQIKQSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
44	1K3VH3-3 0816	IVQIKQSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
45	2K4VH2-8	IVQIKQESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
46	2K4VH1-1	SVKLIQESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
47	2K4VH1-4	SVKLIQESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
48	1C9 VH404-8 1024	QVQLOPSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--DGET			58
49	1C9 VH405-12 1024	QVQLOPSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--DGET			58
50	1C9 VH411-1 1024	QVQLOPSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--DGET			58
51	1C9 VH406-4 1024	QVQLOPSGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--DGET			58
52	1L20VH2-3 0903	QVQLKESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
53	1L20VH2-1 0907	QVQLKESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
54	1L20VH2-3 0910	QVQLKESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
55	1L20VH1-7 0910	DVKLQESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
56	1L20VH1-17-6 0829	DVKLQESGAELLARP GASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--NGDT			58
57	1L5VH003-5-8 0907	EVQLQQSGAALVREGASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--DSET			58
58	1L5VH003-6-3 0907	EVQLQQSGAALVREGASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--DSET			58
59	1L5VH001-7-6 0907	EVQLQQSGAALVREGASV KLSCKASGYTTFSYWNQWVKORPGQGLEWIGA IYPG--DSET			58

12/15

60	1L5VH001-6-5 0907	EVQLOQSGAALVRPGASVVLCKASGYSETSYWVQRPGLGLEWIGNIHPSP--DSET	58
61	1L5VH001-6-11	EVQLOQSGAALVRPGASVVLCKASGYSETSYWVQRPGLGLEWIGNIHPSP--DSET	58
62	1L5VH003-6-2 0910	EVQLOQSGAALVRPGASVVLCKASGYSETSYWVQRPGLGLEWIGNIHPSP--DSET	58
63	1L5VH001-6-12 0907	EVQLOQSGAALVRPGASVVLCKASGYSETSYWVQRPGLGLEWIGNIHPSP--DSET	58
64	1L5VH003-3-4 0907	EVQLOQSGAALVRPGASVVLCKASGYSETSYWVQRPGLGLEWIGNIHPSP--DSET	58
65	1L5VH003-3-8 0907	EVQLOQSGAALVRPGASVVLCKASGYSETSYWVQRPGLGLEWIGNIHPSP--DSET	58
66	CTC2 VH	EVQLOQPGSEFVKPGASVRLSRSSGYTTTIEWVQRPQGLEWIGNIYPG--DAAT	58
67	CTD2 VH	EVQLOQPGSEFVKPGASVRLSRSSGYTTTIEWVQRPQGLEWIGNIYPG--DAAT	58
68	CTA5 VH	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
69	CTB11 VH	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
70	1N23VH3-5	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
71	1N23VH3-7	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
72	1N23VH2-1	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
73	1K23VH2-1 0910	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
74	1K23VH1-4 0907	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
75	1K23VH1-10 0907	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
76	1N23VH1-5	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
77	1K23VH8-4 0907	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
78	1K23VH8-5 0907	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
79	1K23VH8-9 0907	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
80	1E9 VH1E3	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
81	1E9 VH1D5	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60
82	1A12 VH	EVRLVETGGGLVQPEGSILKISCAASCTENANAMAVRQVPGKGLEWAVIRSKTRVIAL	60

FIG. 10A Cont.

13/15

62	115VH003-6-2	0910	RINQKFKD ATLTVIKSSSTAYMQLSSPTSEDSAVVYACRY---DRSYTDYNGQGTTLVSS	118
63	115VH001-6-12	0907	RINQKFKD ATLTVIKSSSTAYMQLSSPTSEDSAVVYACRY---DRSYTDYNGQGTTLVSS	118
64	115VH003-3-4	0907	RINQKFKD ATLTVIKSSSTAYMQLSSPTSEDSAVVYACRY---DRSYTDYNGQGTTLVSS	118
65	115VH003-3-8	0907	RINQKFKD ATLTVIKSSSTAYMQLSSPTSEDSAVVYACRY---DRSYTDYNGQGTTLVSS	118
66	CTC2	VH	RINQKFKD ATLTVIKSSSTAYMQLSSPTSEDSAVVYACRY---DRSYTDYNGQGTTLVSS	118
67	CTD2	VH	RINQKFKG KATLTVSDTSSTAYMHLFSITSDDSAVYCVRS-----GDTWNGQGTTLVSS	113
68	CTA5	VH	RINQKFKG KATLTVSDTSSTAYMHLFSITSDDSAVYCVRS-----GDTWNGQGTTLVSS	113
69	CTB11	VH	RINQKFKG KATLTVSDTSSTAYMHLFSITSDDSAVYCVRS-----GDTWNGQGTTLVSS	113
70	1N23VH3-5		YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
71	1N23VH3-7		YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
72	1N23VH2-1		YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
73	1K23VH2-1	0910	YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
74	1K23VH1-4	0907	YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
75	1K23VH1-10	0907	YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
76	1N23VH1-5		YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
77	1K23VH8-4	0907	YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
78	1K23VH8-5	0907	YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
79	1K23VH8-9	0907	YYADSVVKDR ETISRDDSQSMYLQMFENIKTEDTAMYCVRD-----GWWNGQGTSVTVSS	115
80	1E9	VH1E3	YIVDSVKGR ETISRDMAKNSLYLQMNNSIRAEADTAVVYARGGNS-----YIGNGQGTTLVVSS	116
81	1E9	VH1D5	YIVDSVKGR ETISRDMAKNSLYLQMNNSIRAEADTAVVYARGGNS-----FRDNGQGTTLVVSS	116
82	1A12	VH	YIVDSVKGR ETISRDMAKNSLYLQMNNSIRAEADTAVVYARGDRED-----GMDVNGQGTTLVVSA	117

FIG. 10B Cont.

15/15

Unique Light Chain CDR Sequence Alignments

SEQ ID NO.	CDR1	SEQ ID NO.	CDR2	SEQ ID NO.	CDR3
83	QSLVHSNGNTY	89	KVS	96	SQSAHVP-WT
84	QNIVHSNGNTY	90	KIS	97	SQSTHVP-PT
85	KSLLHSNGNTY	91	RMS	98	FQGSHV--LT
86	QNI-----NSF	92	HMS	99	MQHLEYP-LT
87	SNI----GNNY	93	RTN	100	LQQLEYP-FT
88	KL-----GNKY	94	DNN	101	MQGLEYP-LT
		95	QDK	102	LQYDDFP-LT
				103	SSYTSSSSWV
				104	QAWDSRTVVI

FIG. 11

Unique Heavy Chain CDR Sequence Alignments

SEQ ID NO.	CDR1	SEQ ID NO.	CDR2	SEQ ID NO.	CDR3
105	GYTFTSYW	113	IYPG--NGDT	122	ARG-----GIAWFAY
106	GFTFTNYW	114	IYPG--NGET	123	ASGYP-----YFAY
107	GYSFTSYW	115	IYPG--DGET	124	AKG--D--GNFWFAY
108	GYTFTTFW	116	IHPS--DSET	125	ACRY-D---RSYFDY
109	GFTFNANA	117	IYPG--DAAT	126	VRS-----GDF
110	GDSVTSGY	118	IRSKTRNYAI	127	VR---D-----GWW
111	GFTFSSYW	119	ISYS---GNT	128	ARYNS-LLRLGAMDY
112	GFTFSNYG	120	IKRD--GSEK	129	ARGGN-S-----YVG
		121	ISYD--GINK	130	ARGGN-S-----FRD
				131	AKDRED----G-MDV

FIG. 12